We are looking for a highly motivated Research Technician to join the Kubicek laboratory at CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna. This is an opportunity to work on cutting edge research projects at the interface of cell biology, epigenetics and chemical biology.
In this position you will work closely with postdocs in the lab to systematically explore the epigenetic and metabolic mechanisms governing cancer cell proliferation, with the aim of identifying and characterising synthetic lethal therapeutic targets. This project is based on our recent publications of novel pathways phenocopying BRD4 inhibition (Sdelci et al. Nat. Chem. Biol. 2016) and of synthetic lethality in prostate cancer cells (Licciardello et al. Nat. Chem. Biol. 2017).
We use a variety of techniques of functional analysis and detailed molecular characterization of chromatin pathways in cancer, including proteomics, metabolomics, transcriptomics, and epigenomics, as well as chemical and genetic screening.
You will have a degree in either biology or chemistry (MTA, CTA, B.Sc., M.Sc., Mag., DI) and previous experience with molecular, cellular or chemical biology, biochemistry and epigenetics. Expertise in genome editing, small molecule probe development, metabolomics, functional screening or bioinformatics is considered a plus. The working language at CeMM is English, and excellent written and oral communication skills as well as high accuracy, reliability and excellent interpersonal and organizational skills are a requirement.
The Research Group:
The Kubicek laboratory is working on the role of chromatin in the definition of cell types and cell states, and the use of chemistry to modulate epigenetic states. In addition to cancer biology, projects in the laboratory focus on the development of chromatin-targeting chemical probes, and the generation of insulin-producing beta cells from other cell types. Through shared tools and technologies, these efforts are highly synergistic, having resulted in the first single-cell transcriptomes from primary human pancreatic islets (Li et. al EMBO Rep. 2016) and the identification of artemisinins as compounds causing alpha cell transdifferentiation (Li et al. Cell 2017).
In this role you will have the opportunity to work in a highly innovative research environment and collaborate closely with other groups at CeMM. Our unique setup includes high throughput screening at PLACEBO (Platform Austria for Chemical Biology), and access to chemistry, mass spectrometry, bioinformatics, next generation sequencing, and clinical expertise.
We offer a competitive salary: this position will be paid according to the guidelines of the Austrian Science Fund. The annual gross salary will be € 31,000, on a full time basis. In addition, the position comes with comprehensive health insurance, and an additional in-house health care service.
CeMM is a biomedical flagship institute in the heart of Europe, Vienna. We are committed to highest scientific standards and provide an international environment representing approximately 40 nationalities. The working language is English. CeMM has been ranked by The Scientist as one of the Best Places to Work Academia worldwide (link: http://goo.gl/51VMO). In the past 3 years CeMM groups published numerous ground-breaking studies in prestigious journals such as Science, Cell, Nature, New England Journal of Medicine, Nature Immunology, Immunity etc. CeMM is located within the medical campus of Vienna and operates several technology platforms (chemical biological screening, proteomics, metabolomics, next-generation sequencing) as well as extensive bioinformatics infrastructure.
To apply for this position, please click on the link below and submit your application documents, including a cover letter, your CV, and the names and contact details of 2 referees: https://cemm.jobbase.io/job/400y6n16
CeMM aims to promote equality of opportunity for all with the right mix of talent, competences and potential. We welcome applications from candidates with diverse backgrounds.
The closing date for applications is: July 30, 2017